The "Intravenous" Milestone: How 2026 is Moving Beyond Direct Tumor Injections.
By mid-2026, the industry has officially entered the era of "Systemic Virotherapy." This year, the focus is on the successful deployment of "Stealth" Viral Platforms that are engineered to survive in the bloodstream without being neutralized by the liver or the immune system. This innovation is a primary driver for the market, as it allows oncolytic viruses to treat metastatic "Stage IV"...
0 Комментарии 0 Поделились 10 Просмотры 0 предпросмотр